TrialThe lancet. Diabetes & endocrinology2022

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.

Andrea M Haqq et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.